News

GLP-1 agonists may be an effective therapy to avoid severe liver disease in those with concurrent type 2 diabetes.

A deep dive into the complex playing field for M&A and partnering pursuits in today’s increasingly make-or-break landscape for biopharma innovation.

As providers and healthcare professionals recognize the potential of long-acting injectables to fight the opioid epidemic, many are actively transitioning from oral options to injectables.

The Identification of Medicinal Product framework seeks to establish a common language for identifying, documenting, and exchanging information about medicinal products.

Concerns regarding hypoglycemia potentially linked to a counterfeit version of Ozempic come at a time in which reports have grown regarding the improper use of GLP-1 receptor agonists for the purpose of cosmetic weight loss.

Dupixent is now the first and only treatment option for eosinophilic esophagitis in patients aged 1 and older, weighing at least 15 kg.

As technology continues to advance, investigators explore the legal protocol for how to handle AI-responsible injuries.

Zynrelef was initially approved by the FDA for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours following bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty.

Tesamorelin (Egrifta) was initially approved by the FDA in November 2010 for the treatment of lipodystrophy in patients also diagnosed with HIV.

Patients treated with Tremfya (guselkumab) saw major improvements in scalp psoriasis clearance, itch reduction, and patient-reported health-related quality of life.

Treatments required to have updated warnings include all FDA-approved CAR T-cell therapies and licensed BCMA-directed and CD19-directed genetically modified autologous CAR T-cell immunotherapies.

The FDA assigned Autolus Therapeutics' biologics license application for obecabtagene autoleucel with a Prescription Drug User Fee Act date of November 16, 2024.

The definitive merger agreement was reached in October 2023, with Bristol Myers Squibb acquiring Mirati for $58 per share in cash, for a total equity value of $4.8 billion.

Offerings include treatment plans for a considerable number of illnesses and conditions, company says.

Study describes how a game theoretic model can successfully analyze how adoption of blockchain technology can reveal quality information.

Data from prior Phase II study showed signs of pridopidine slowing disease progression in patients with amyotrophic lateral sclerosis.

NK010, which showed promising anti-tumor activity and safety in preclinical studies, will be evaluated in a Phase I clinical trial for ovarian cancer.

The addressable treatment market for osteopenia is projected to reach more than $30 billion in the United States and $100 billion globally.

Acquisition is expected to strengthen company’s CDMO business, while establishing a footprint in the generics space.

Phase Ib study evaluated satri-cel in patients with advanced gastric/gastroesophageal cancer or pancreatic cancer who had progressed on or were intolerant of prior systemic therapy.

Opdivo (nivolumab) with Yervoy (ipilimumab) showed a 79% drop in the risk of disease progression or death compared to chemotherapy in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer.

Sandoz will buy Cimerli (ranibizumab-eqrn), an interchangeable biosimilar to Lucentis (ranibizumab), for an upfront cash payment of $170 million.

Today's approval amends the accelerated approval granted by the FDA in April 2019 to Balversa (erdafitinib) for patients with metastatic urothelial carcinoma with susceptible FGFR2 or FGFR3 alterations following prior treatment with platinum-containing chemotherapy.

Experts explore ways in which the financial sector refined the healthcare landscape, including its evolutions throughout the years.

In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the changing role of PBMs and recent price structure overhauls.

Data presented at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium show first-line Lutathera plus long-acting release octreotide lowered the risk of disease progression or death by 72% in patients with advanced gastroenteropancreatic neuroendocrine tumors.

All healthcare stakeholders must participate to dismantle barriers and ensure access to medicines that save lives.

Application seeks approval for tumor-treating fields therapy combined with either an immune checkpoint inhibitor or docetaxel in patients with metastatic non-small cell lung cancer following progression on or after the use of platinum-based therapy.